Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401293 | 0.87 | CYP1A2 (0.48) | ALDH1A1KDM4ECYP1A2LMNASMN1; SMN2 | |
| SCHEMBL28506559 | 0.85 | CYP1A2 (0.47) | ALDH1A1KDM4ECYP1A2LMNASMN1; SMN2 | |
| SCHEMBL4570474 | 0.79 | ALDH1A1 (0.46) | ALDH1A1KDM4ECYP1A2LMNASMN1; SMN2 | |
| SCHEMBL9912008 | 0.79 | PDE2A (0.52) | ALDH1A1KDM4ECYP1A2LMNASMN1; SMN2 | |
| SCHEMBL3175016 | 0.79 | LMNA (0.55) | ALDH1A1KDM4ECYP1A2LMNASMN1; SMN2 | |
| SCHEMBL12101919 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4ECYP1A2LMNASMN1; SMN2 | |
| SCHEMBL18978202 | 0.77 | KDM4E (0.39) | ALDH1A1KDM4ECYP1A2LMNASMN1; SMN2 | |
| SCHEMBL11583546 | 0.77 | ALDH1A1 (0.39) | ALDH1A1KDM4ECYP1A2LMNASMN1; SMN2 | |
| SCHEMBL2633440 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4ECYP1A2LMNASMN1; SMN2 | |
| SCHEMBL10645292 | 0.77 | NPC1 (0.50) | ALDH1A1KDM4ECYP1A2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283472-B1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | UNIV INDIANA RES & TECH CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3283472-B1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | UNIV INDIANA RES & TECH CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10273228-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273228-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| EP-3283472-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | Indiana University Research&Technology Corporation (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
| EP-2143724-B1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-20090306116-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| CN-101304996-A | Pyrimidine Derivatives Inhibiting IGF-1R Tyrosine Kinase Activity | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | CN | disclosed |
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008117051-A1 | S-6-METH0XY-2- (2- (3- (PYRIMID-2-YL) IS0XAZ0L-5-YL) PYRROLIDIN-1-YL) -4- (5-METHYL-IH-PYRAZOL-S-YLAMINO) PYRIMIDINE AND POLYMORPHIC FORMS THEREOF AS MODULATORS OF THE INSULIN-LIKE GROWTH | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| US-20080171742-A1 | 4-(Pyrid-2-Yl) Amino Substituted Pyrimidine as Protein Kinase Inhibitors | ASRAZENECA (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1931662-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | AstraZeneca AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| CN-101198603-A | 4-(pyrid-2-yl) amino substituted pyrimidine as protein kinase inhibitors | ASTRAZENECA AB (SE) | 2008-06-11 | — | — | CN | disclosed |
| EP-1871771-A1 | 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007031745-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006109026-A1 | 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | HAVCR2, MAVS, HCCS | ALDH1A1 4332/4885KDM4E 3876/4885CYP1A2 3869/4885 |
| US-20080171742-A1 | 4-(Pyrid-2-Yl) Amino Substituted Pyrimidine as Protein Kinase Inhibitors | IGF1R, IGFBP1, IRS1 | ALDH1A1 1905/4885KDM4E 2320/4885CYP1A2 3400/4885 |
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | UGT2B7, UGT1A7, CYP3A7 | ALDH1A1 790/4885KDM4E 2992/4885CYP1A2 331/4885 |
| US-10273228-B2 | Hepatitis B viral assembly effectors | HAVCR2, MAVS, HCCS | ALDH1A1 4332/4885KDM4E 3876/4885CYP1A2 3869/4885 |
| US-20090306116-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | IGF1R, IGFBP1, IRS1 | ALDH1A1 1159/4885KDM4E 3290/4885CYP1A2 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.